Abstract
Adiponectin is widely known as an adipocytokine with therapeutic potential for its markedly protective function in the pathogenesis of obesity-related disorders, metabolic syndrome, systemic insulin resistance, cardiovascular disease and more recently carcinogenesis. In the present study, we show that adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Further analysis of the underlying molecular mechanisms revealed that adiponectin treatment increased AMP-activated protein kinase (AMPK) phosphorylation and activity as evident by increased phosphorylation of downstream target of AMPK, acetyl-coenzyme A carboxylase and inhibition of p70S6 kinase (S6K). Intriguingly, we discovered that adiponectin treatment increases the expression of tumor suppressor gene LKB1 in breast cancer cells. Overexpression of LKB1 in breast cancer cells further increased adiponectin-mediated phosphorylation of AMPK. Using isogenic LKB1 knockdown cell line pair, we found that LKB1 is required for adiponectin-mediated modulation of AMPK–S6K axis and more importantly, inhibition of adhesion, migration and invasion of breast cancer cells. Taken together these data present a novel mechanism involving specific upregulation of tumor suppressor gene LKB1 by which adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Our findings indicate the possibility of using adiponectin analogues to inhibit invasion and migration of breast cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Sakamoto K, Bayascas JR . (2006). LKB1-dependent signaling pathways. Annu Rev Biochem 75: 137–163.
Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE et al. (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909–915.
Arditi JD, Venihaki M, Karalis KP, Chrousos GP . (2007). Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39: 9–13.
Baas AF, Boudeau J, Sapkota GP, Smit L, Medema R, Morrice NA et al. (2003). Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 22: 3062–3072.
Barb D, Pazaitou-Panayiotou K, Mantzoros CS . (2006). Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs 15: 917–931.
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE . (2001). The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947–953.
Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M et al. (2003). MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 22: 5102–5114.
Boudeau J, Scott JW, Resta N, Deak M, Kieloch A, Komander D et al. (2004). Analysis of the LKB1-STRAD-MO25 complex. J Cell Sci 117: 6365–6375.
Cacicedo JM, Yagihashi N, Keaney Jr JF, Ruderman NB, Ido Y . (2004). AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 324: 1204–1209.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ . (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625–1638.
Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY et al. (2006). Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237: 109–114.
Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien P E, Dixon JB et al. (2005). Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab 90: 3665–3672.
Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL . (2001). Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 92: 720–729.
Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R . (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345: 271–279.
Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y et al. (2008). Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20: 971–977.
Fantuzzi G . (2005). Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115: 911–919; quiz 920.
Fenton H, Carlile B, Montgomery EA, Carraway H, Herman J, Sahin F et al. (2006). LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 14: 146–153.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. (2001). Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005–2010.
Goldstein BJ, Scalia R . (2004). Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89: 2563–2568.
Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP . (2008). Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98: 370–379.
Hardie DG . (2004). The AMP-activated protein kinase pathway—new players upstream and downstream. J Cell Sci 117: 5479–5487.
Hardie DG . (2005). New roles for the LKB1-> AMPK pathway. Curr Opin Cell Biol 17: 167–173.
Hezel AF, Bardeesy N . (2008). LKB1; linking cell structure and tumor suppression. Oncogene 27: 6908–6919.
Hu E, Liang P, Spiegelman BM . (1996). AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697–10703.
Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF . (2004). T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101: 10308–10313.
Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F et al. (2008). Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology 53: 484–487.
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R et al. (1998). Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18: 38–43.
Kelesidis I, Kelesidis T, Mantzoros CS . (2006). Adiponectin and cancer: a systematic review. Br J Cancer 94: 1221–1225.
Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A et al. (2007). Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 92: 1041–1048.
Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT et al. (2008). Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 29: 2195–2202.
Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP et al. (2005a). Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309: 99–109.
Luo Z, Saha AK, Xiang X, Ruderman NB . (2005b). AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69–76.
Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D et al. (2005). Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111: 747–753.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K . (1996). cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 221: 286–289.
Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM et al. (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89: 1102–1107.
Martin DE, Hall MN . (2005). The expanding TOR signaling network. Curr Opin Cell Biol 17: 158–166.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I . (2004). Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24: 29–33.
Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y et al. (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9: 5699–5704.
Motoshima H, Goldstein BJ, Igata M, Araki E . (2006). AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574: 63–71.
Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M . (1996). Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120: 803–812.
Nakayama S, Miyoshi Y, Ishihara H, Noguchi S . (2008). Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat 112: 405–410.
Petrelli JM, Calle EE, Rodriguez C, Thun MJ . (2002). Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13: 325–332.
Phoenix KN, Vumbaca F, Claffey KP . (2009). Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113: 101–111.
Rose DP, Komninou D, Stephenson GD . (2004). Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5: 153–165.
Ruvinsky I, Meyuhas O . (2006). Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31: 342–348.
Sapkota GP, Boudeau J, Deak M, Kieloch A, Morrice N, Alessi DR . (2002). Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. Biochem J 362: 481–490.
Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, Williams MR et al. (2001). Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. J Biol Chem 276: 19469–19482.
Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D et al. (2007a). Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497–2507.
Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM et al. (2008). Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 68: 9712–9722.
Saxena NK, Vertino PM, Anania FA, Sharma D . (2007b). Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 282: 13316–13325.
Schaffler A, Scholmerich J, Buechler C . (2007). Mechanisms of disease: adipokines and breast cancer—endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 3: 345–354.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF . (1995). A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270: 26746–26749.
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA et al. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329–3335.
Shen Z, Wen XF, Lan F, Shen ZZ, Shao ZM . (2002). The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin Cancer Res 8: 2085–2090.
Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H et al. (2003). Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226–228.
Steeg PS, Theodorescu D . (2008). Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5: 206–219.
Swarbrick MM, Havel PJ . (2008). Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6: 87–102.
Takahata C, Miyoshi Y, Irahara N, Taguchi T, Tamaki Y, Noguchi S . (2007). Demonstration of adiponectin receptors 1 and 2 mRNA expression in human breast cancer cells. Cancer Lett 250: 229–236.
Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP . (2002). Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). Hum Mol Genet 11: 1497–1504.
Vona-Davis L, Rose DP . (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14: 189–206.
Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL et al. (2006). Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66: 11462–11470.
Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ et al. (2005). Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280: 18341–18347.
Witters LA, Kemp BE, Means AR . (2006). Chutes and Ladders: the search for protein kinases that act on AMPK. Trends Biochem Sci 31: 13–16.
Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ . (2003). The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112: 91–100.
Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. (2003a). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–769.
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. (2002). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288–1295.
Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K et al. (2003b). Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461–2468.
Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB . (2006). Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55: 2562–2570.
Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M . (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269–10273.
Zhong D, Liu X, Khuri FR, Sun SY, Vertino PM, Zhou W . (2008). LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. Cancer Res 68: 7270–7277.
Zhuang Y, Miskimins WK . (2008). Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3: 18.
Acknowledgements
This study was supported by NIH LRP (grant to LTS), NIDDK NIH (K01DK076742 to NKS), NCI NIH (5P01CA116676-030002 to WZ), NCI NIH (R01CA131294 to DS), Wilbur and Hilda Glenn Foundation (grant to DS), CDMRP BCRP (grant BC030963 to DS), The Susan G Komen for the Cure (grant BCTR0503526 to DS), Emory University Research Council (DS), BJ Foundation (DS) and Mary K Ash Foundation (research grant to DS).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Taliaferro-Smith, L., Nagalingam, A., Zhong, D. et al. LKB1 is required for adiponectin-mediated modulation of AMPK–S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28, 2621–2633 (2009). https://doi.org/10.1038/onc.2009.129
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.129
Keywords
This article is cited by
-
Adiponectin suppresses tumor growth of nasopharyngeal carcinoma through activating AMPK signaling pathway
Journal of Translational Medicine (2022)
-
Adiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming
Journal of Experimental & Clinical Cancer Research (2022)
-
Adipose Stroma Accelerates the Invasion and Escape of Human Breast Cancer Cells from an Engineered Microtumor
Cellular and Molecular Bioengineering (2022)
-
Metabolic pathways in obesity-related breast cancer
Nature Reviews Endocrinology (2021)
-
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB
npj Breast Cancer (2021)